Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2026 09:31 ET | Source: Agios Pharmaceuticals, Inc.

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

Agios announces the submission of its sNDA to the FDA for the U.S. accelerated approval of mitapivat in sickle cell disease
May 12, 2026 09:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Agios announces new data on mitapivat will be featured in oral and poster presentations at EHA 2026 in Stockholm, Sweden, June 11-14, 2026
April 29, 2026 06:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Agios announces first quarter 2026 financial results and provides business update.
April 22, 2026 19:54 ET | Source: Exicure, Inc.

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Exicure enters co-development agreement with Adbiotech to advance Burixafor (GPC-100) combination therapies across multiple indications.
April 20, 2026 05:19 ET | Source: Novo Nordisk A/S

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease

Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care1Haemoglobin response was superior with...
March 31, 2026 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease
February 12, 2026 06:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Agios (Nasdaq: AGIO) announces financial results and updates for the fourth quarter and year ended December 31, 2025.
February 05, 2026 11:40 ET | Source: Spherix Global Insights

Spherix Global Insights Reveals Persistent High Disease Burden and Heavy Reliance on Pain Management in U.S. Sickle Cell Disease Despite Awareness of Disease-Modifying Therapies

Exton, PA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- New research from Spherix Global Insights underscores the profound and multifaceted burden faced by patients living with sickle cell disease (SCD),...
January 12, 2026 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Agios today announced its 2026 strategic priorities and key milestones anticipated during the year.
December 22, 2025 11:58 ET | Source: AB Science

AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040

PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S...